Stocktoria
Vivos Therapeutics, Inc. VVOS
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-12-11
Vivos Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M | $13.1M | $11.4M |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M | $10.4M | $8.7M |
| R&D expense | $100,000 | $100,000 | $100,000 | $200,000 | $200,000 | — | — |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M | -$12.0M | -$10.6M |
| Interest expense | $1.4M | — | — | — | $14,000 | $96,000 | $137,876 |
| Net income | -$21.2M | -$11.1M | -$13.6M | -$23.8M | -$20.3M | -$12.1M | -$10.8M |
| EPS (diluted) | $-2.07 | $-2.22 | $-11.14 | $-25.90 | — | — | — |
| Operating cash flow | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M | -$5.7M | -$5.3M |
| Free cash flow | -$17.6M | -$13.3M | -$12.7M | -$20.5M | -$18.1M | -$5.8M | -$5.5M |
| Cash & equivalents | $2.0M | $6.3M | $1.6M | $3.5M | $24.0M | $18.2M | $469,353 |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M | $25.3M | $7.6M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M | $8.4M | $9.2M |
| Shareholders' equity | -$1.6M | $8.0M | $411,000 | $4.8M | $25.5M | $16.9M | -$2.9M |
Growth · year-over-year · Revenue CAGR 7.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +16.0% | +8.9% | -13.9% | -5.1% | +29.2% | +14.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.